Swift (Permethrin) is commonly used to help with the conditions of scabies and pediculosis (lice infestation). It is applied across therapeutic domains where additional symptomatic support is needed to manage external parasites and their eggs, which may be part of symptomatic management.

Swift is primarily used for managing external human parasites, specifically the mites that cause scabies and the lice responsible for pediculosis, including head, body, or pubic lice. Its use is relevant in conditions presenting with acute or disruptive episodes, where supporting efforts toward clearance is a primary therapeutic goal. This provides valuable support for easing symptom clusters that may become intense or disruptive, such as severe and persistent itching (pruritus) that interferes with daily functioning. By providing support for the elimination of the parasites, the treatment assists with maintaining functional stability and contributes to the resolution of associated skin manifestations.

“The medication is considered relevant in managing the transmission of these contagious conditions in situations involving both the patient and close contacts.”

Quick Fact: Relief for Nocturnal Itching Swift is commonly used to help with symptomatic relief, particularly the exacerbated itching that may intensify at night, which assists with maintaining functional stability and supports general well-being during symptomatic phases.

Regulatory References

1. NIH MedlinePlus Drug Information

Who Can and Cannot Use Swift? (Permethrin Topical)

The population eligibility for Swift is defined by regulatory documents, establishing clear groups for whom use is permitted, restricted, or strictly prohibited.

Absolute Contraindications

Swift is contraindicated and must not be used by individuals with a known hypersensitivity to the active ingredient permethrin, any related synthetic pyrethroid or pyrethrin compound, or any of the product’s inactive components (excipients).

Age-Related Eligibility and Restrictions

The medicine is approved for use in adults and the elderly. For the pediatric population, it is established as safe and effective for children two months of age and older.

• Infants: Safety and effectiveness for infants less than two months of age have not been established by regulatory authorities.
• Young Children: Treatment for children aged 2 months to 23 months requires close medical supervision due to limited clinical experience in this specific age range.

Conditional Use Populations

• Pregnancy: Use during pregnancy is conditional and should occur only if clearly needed, based on regulatory guidance.
• Lactation: Consideration must be given to discontinuing nursing temporarily or withholding the drug while the mother is breastfeeding, as it is unknown if the drug is excreted in human milk.

No explicit restrictions are noted in the official label regarding use in patients with renal impairment, as the drug is excreted as inactive metabolites.

The official interaction profile for Permethrin topical is characterized by minimal systemic risk, consistent with the low level of absorption (typically less than two percent) after application. Due to this minimal systemic exposure, regulatory documents state that systemic drug-drug interactions, including those related to metabolic enzymes or drug transporters, are neither known nor expected with oral or injectable medicines.

The documented interaction constraints are primarily focused on the site of application or relate to class prohibitions.

Interaction Type	Documented Restriction or Finding
Systemic PK Interactions	Not expected due to minimal absorption.
Topical Pharmacodynamic	Activity may be decreased by using shampoos containing conditioner immediately prior to application.
Timing Requirement	Topical corticosteroids used for associated eczematous reactions should be withheld prior to treatment.

Formal labeling includes a contraindication prohibiting the use of Swift if a known hypersensitivity exists to Permethrin or any substance belonging to the pyrethroid or pyrethrin chemical class. This is a safety prohibition based on class-related restrictions.

A further constraint involves the product's inactive ingredients. Excipients in the cream formulation, such as liquid paraffin, can affect certain medical devices. Specifically, they may reduce the functioning and reliability of products made of latex, such as condoms or diaphragms, if used concurrently with the treatment area.

The overall regulatory interaction structure reflects the drug's topical delivery, emphasizing local efficacy and specific safety prohibitions over complex systemic pathways.

Swift: How It Works

Disrupting Arthropod Neuronal Signaling

This drug operates by targeting the Voltage-Gated Sodium Channels (VGSCs) exclusively in the ectoparasite's nerve cells. As a channel modulator, it initiates a specific mechanism of action: it binds to the channel's alpha subunit, critically delaying its closure (inactivation). This disruption results in a sustained, high-magnitude influx of sodium ions into the neuron. This molecular action immediately causes neuronal hyperexcitability and uncontrolled, repetitive nerve firing.

Cascade to Prolonged Neuromuscular Paralysis

The hyperexcitability triggered by the prolonged ion flow rapidly escalates into a complete neurotoxic cascade. The relentless, uncontrolled signaling exhausts the parasite's central and peripheral nervous system, quickly transitioning the organism from hyperactivity and spasms to prolonged neuromuscular paralysis. This collapse of motor function is the direct physiological consequence of the mechanism.

Mechanistic Constraints and Resistance

The mechanism's effectiveness is biologically constrained by the target parasite itself. The drug's ability to bind can be weakened by kdr mutations (structural changes in the VGSC) or by the parasite's enhanced capacity for metabolic detoxification (e.g., via Cytochrome P450 enzymes). These factors prevent the drug from achieving the critical molecular interaction needed to fully initiate the neurotoxic cascade.

Swift is a topical pharmaceutical preparation containing Permethrin, designated for cutaneous use only for treating external parasitic infestations. The administration protocol is established to ensure the correct strength and contact time are used for the two primary indications.

The two available formulations define the application area and duration. The 5% Cream, used for scabies, is typically applied as a single application over the body from the neck to the soles of the feet in adults, or including the scalp in infants and geriatric patients. This application must remain on the skin for 8 to 14 hours before being washed off. Conversely, the 1% Lotion, used for pediculosis, is applied to the hair and scalp for a mandatory 10 minutes before rinsing. For lice treatment, hair must be shampooed and rinsed, but not conditioned, before the medication is applied. Care must be taken to avoid contact with the eyes or mucous membranes during application.

Swift's usage schedule is not a maintenance regimen. A single application is considered the standard course of treatment. Re-treatment is not routine and is only administered if live parasites are observed after a minimum interval (e.g., 7 days for lice, or up to 14 days for scabies). The 5% strength is approved for children 2 months of age and older, while the 1% strength is approved for children 2 years of age and older.

Indication	Required Strength	Mandatory Contact Time
Scabies	5% Cream	8 to 14 hours
Pediculosis (Lice)	1% Lotion	10 minutes

Swift: Recent Clinical Evidence

Recent clinical research has primarily focused on the investigational compound depemokimab (often referred to as 'Swift' in its trial phase) as an ultra-long-acting anti-IL-5 biologic therapy.

Core Findings from Phase III Trials

Clinical trials known as SWIFT-1 and SWIFT-2 were large-scale, 52-week, randomized, double-blind, placebo-controlled studies that evaluated the compound in adults and adolescents with severe, uncontrolled asthma associated with type 2 inflammation.

• Annual Exacerbations: Both SWIFT-1 and SWIFT-2 met their primary endpoints, with studies reporting a statistically significant reduction in the annual rate of clinically significant asthma exacerbations over the 52-week period when compared with placebo (when added to standard care). The pooled analysis suggested a notable reduction in exacerbation frequency.
• Severe Outcomes: A secondary finding from the pooled analysis suggested a reduction in clinically significant exacerbations that required hospitalization or an emergency department visit compared to the placebo group. These outcomes are considered nominally significant as they were not the primary statistical focus.

---

Other Research Areas

Research Area	Findings and Status
Inflammation Markers	Studies have noted that the treatment was associated with a sustained suppression of key markers of type 2 inflammation, which is known to drive asthma symptoms.
Safety and Tolerability	Across both trials, the overall incidence and severity of reported treatment-emergent adverse events were generally similar between participants receiving the compound and those receiving the placebo.
Long-Term Dosing	The compound's extended half-life has been investigated for its potential to support dosing intervals of six months, offering a reduced frequency of administration compared to previously studied compounds.

These data reflect the outcomes observed in specific research settings and patient populations. Individuals should discuss the clinical evidence and suitability of treatment options with a healthcare provider.

Key Studies & References

1. Depemokimab for severe eosinophilic asthma (SWIFT-1): A randomized, double-blind, placebo-controlled, phase 3 trial

Common questions about Swift (FAQ)

Q: How quickly do people usually start feeling the effects of Swift?

A: Official information indicates that the itching associated with the underlying infestation may continue for up to 2 to 4 weeks after the Swift treatment has been completed. This lingering sensation is often a temporary reaction to the remains of the mites and does not automatically mean the treatment failed or that the need for another application is required.

Q: Can Swift be taken with vitamins or supplements?

A: Regulatory documents state that systemic drug interactions are not expected because only very minimal amounts of the topical medication are absorbed into the bloodstream. Official guidance suggests providing a healthcare provider with a complete list of all products, including vitamins, supplements, and herbal products.

Q: If I miss a dose of Swift, what does the official leaflet say to do?

A: Since Swift is a single-application treatment and not a daily medication, the concept of a 'missed dose' does not typically apply to the overall regimen. If an area of the body was missed during the application process, official guidance generally advises applying the medication to that missed area. For questions about re-treating the entire infestation, official guidance outlines following the specific instructions provided for observing live parasites.

Q: Are there any common over-the-counter pain relievers that interact with Swift?

A: According to the official product information, systemic interactions with oral medications, including common over-the-counter (OTC) pain relievers, are not expected. This is due to the drug's low systemic absorption. Official labeling suggests patients provide a complete list of all medications to their doctor.

Q: What should be done if someone has an allergic reaction to Swift?

A: If signs of a serious allergic reaction occur after applying the product, such as hives, difficulty breathing, or swelling of the face, official sources direct patients to seek emergency medical attention right away. Contacting a doctor is generally recommended if any skin irritation persists or worsens after the treatment is complete.

Q: What is the official dosage strength for Swift?

A: The official documentation indicates that the required strength is dependent on the condition being treated. The medication is available in a 5% concentration, which is typically prescribed for scabies, and a 1% concentration, which is used for head lice and is often available over-the-counter.

Q: Are there different versions or brands of Swift available?

A: Yes, evidence indicates that the active ingredient in Swift, Permethrin, is available in multiple topical forms, including cream, lotion, and liquid. Furthermore, Permethrin is available as generic versions, which are often lower-cost alternatives to branded products.

Q: Are the side effects of Swift permanent?

A: Official product labeling describes the most common side effects, such as local burning, tingling, or stinging, as generally mild and temporary reactions that occur immediately after application. Any severe or persistent reaction beyond the expected temporary irritation should be reported to a healthcare professional for evaluation.

Q: Is it true that Swift can affect sleep?

A: Sleep disturbance is not typically listed as a common side effect of Swift's labeled topical use. However, general systemic symptoms such as dizziness and headache have been reported in post-marketing surveillance or in cases of very high exposure to this class of compounds.

Q: Do I need to change my diet while using Swift?

A: Interactions with foods or changes to your diet are not expected when using this topical medication. This is based on the fact that only a minimal amount of the drug is absorbed systemically into the body.

Q: Can you take Swift if you have high blood pressure?

A: According to official product labeling, there are no specific contraindications or warnings listed for individuals with high blood pressure (hypertension). This is consistent with the drug being a topical application with minimal systemic absorption into the bloodstream.

Q: Is Swift considered a controlled substance?

A: Official documentation confirms that the active ingredient in Swift, Permethrin topical, is not classified as a controlled substance by regulatory agencies.

Q: Can drinking alcohol while on Swift make the side effects worse?

A: Warnings regarding the consumption of alcohol are not typically included in the official labeling for this topical medication. This is consistent with the drug having minimal systemic absorption and therefore a low likelihood of interaction within the body.

Q: Is it normal to feel tired after starting Swift?

A: Tiredness or fatigue is not commonly listed as a typical side effect of the labeled topical treatment. However, general feelings of fatigue have been mentioned in official documents as systemic symptoms sometimes associated with high exposure to pyrethroids.

Q: What happens if a child accidentally takes Swift?

A: If the medication is accidentally swallowed, official guidance indicates that emergency medical attention or contacting a Poison Control Center should occur immediately. In such cases, general supportive measures may be employed by medical professionals.

Q: Does Swift interact with grapefruit juice or other common foods?

A: Official product information indicates that interactions with food substances, including specific items like grapefruit juice, are not expected. This determination is based on the minimal amount of the drug that is absorbed systemically after a topical application.

Q: Is Swift available as a generic medicine?

A: Yes, the active ingredient in Swift, Permethrin, is widely available as a lower-cost generic product.

Q: Can a person take Swift if they have liver problems?

A: Warnings specific to liver problems are generally absent from the official labeling for this medication. This is due to the drug's minimal systemic absorption and its subsequent rapid metabolism into inactive components.

Q: Are there official warnings about driving or operating machinery while using Swift?

A: Warnings against engaging in activities such as driving or operating heavy machinery are not typically listed in the official labeling for Swift. This aligns with the drug's minimal systemic effects following topical use.

Q: Why do some people report feeling dizzy on Swift?

A: Dizziness is listed as a possible adverse reaction, particularly in post-marketing reports or in cases involving high exposure or accidental ingestion of the pyrethroid compound. If such an event occurs, reporting it to a healthcare provider is generally recommended.

Q: How long does Swift stay in the body after the last dose?

A: Only a very small amount—less than two percent—of the drug is absorbed into the bloodstream after topical application. This absorbed amount is then rapidly metabolized into inactive components which are eliminated from the body primarily through the urine.

Q: Are there any specific safety warnings for teenagers taking Swift?

A: Official information states that the drug is approved for patients two months of age and older. Specific safety warnings are primarily focused on the limited clinical experience in infants younger than two months. Teenagers are generally covered under the standard adult population guidance.

Q: Can patients with diabetes safely use Swift?

A: There are no specific contraindications or safety warnings listed in the official documents for patients who have diabetes. This is consistent with the drug being a topical product with minimal absorption into the systemic circulation.

Q: What if I take too much Swift? What are the listed official symptoms?

A: Symptoms of high exposure or overdose are not universally listed, but acute symptoms reported can include vomiting, nausea, convulsions, and dizziness. Official guidance states that emergency medical attention or contacting a Poison Control Center should occur immediately if too much product is used or accidentally ingested.

Q: Are there any known long-term effects of Swift on the heart?

A: Official documents list serious cardiac symptoms, such as an irregular heartbeat, as symptoms to report immediately. However, there are no specific warnings about known long-term cardiac effects resulting from the labeled topical use of Swift.

Q: Can men use Swift if they are planning to have children?

A: Animal reproduction studies cited in official documents have shown no evidence of impaired fertility or harm to the fetus. Male fertility is not a specific contraindication noted in the human labeling for this product.

How to Store and Dispose of Swift (Permethrin Topical)

The official label mandates that Swift (Permethrin Cream/Lotion) must be stored at controlled room temperature, specifically between 20 C and 25 C (68 F and 77 F). Storage conditions must prevent freezing and exposure to excess heat and moisture. The product must be kept in its original container, which must remain tightly closed to maintain product stability.

Storage Restriction	Requirement
Temperature	Do not store above 30 C. Do not freeze.
Container Rule	Keep tightly closed in original packaging.
Child Safety	Store strictly out of the sight and reach of children.

For disposal, unused or expired medication should be discarded through an official drug take-back program. If a take-back option is unavailable, the product should be mixed with an undesirable substance, placed in a sealed bag, and then disposed of in the household trash.